Out-Licensing

We keep science moving for patients, even as our business changes. 
Under the microscope
Under the microscope

When priorities shift…

We’ve intensified our focus on specific disease areas. That means some products in our diversified portfolio of medicines and vaccines have moved outside our strategic focus.

Gaborne Gajdos examines ampules at the Ampule production at the Sanofi plant in Csanyikvolgy, Hungary
Gaborne Gajdos examines ampules at the Ampule production at the Sanofi plant in Csanyikvolgy, Hungary

Opportunities arise

We out-license some of our products to help partners access novel solutions, speed up time-to-market, and explore new business directions. 

Partnering success stories

Corteria

Our exclusive worldwide license agreement with Corteria, a company initially backed by Kurma Partners, centers on two cardiovascular assets designed to treat specific types of heart failure: a CRF2 agonist peptide and an anti-vasopressin mAb. Corteria has recently announced an oversubscribed €65M ($71M1) Series A co-led by OrbiMed and Jeito Capital to advance our prior cardiovascular research into the clinic as a potential interceptive therapy for heart failure.

First Wave BioPharma

For the first time at Sanofi, an out-licensing deal was designed by using AI to reposition a Sanofi asset into a new indication. First Wave Bio signed an exclusive worldwide license for Capeserod, a Phase II program stopped in 2009, to be repurposed in gastrointestinal disorders with significant unmet needs. The new indication was suggested by the combination of Sanofi’s clinical data on Capeserod and the implementation of AI-empowered analyses of the drug’s properties.

Your partnering lead in Out-Licensing

For more information, contact us at OutLicensingBD@sanofi.com

Matthieu Lebrun

Matthieu Lebrun

Global Head of Business Development, Out-Licensing

Rare Disease Partnerships